About this episode
In this continuation of our myeloma series, we build on our prior discussion about myeloma pharmacology, this time discussing how to select the optimal regimen for treatment of our patients. Content: - What are the phases of multiple myeloma treatment? - How do we determine transplant eligibility? - What does doublet, triplet, and quadruplet therapy mean? - What categorizes "high risk" myeloma? - What are the current standards of care for transplant eligible patients? - Where does "CyBorD" fit in for treatment? - When do we consider adding daratumumab? - Links to key trials This episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co. Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast